Pulmonx price target lowered to $15 from $16 at Canaccord

Canaccord lowered the firm’s price target on Pulmonx (LUNG) to $15 from $16 and keeps a Buy rating on the shares. The firm said they reported a relatively in-line first quarter and the company reiterated the 2025 guidance that it already provided. The company is confident that its OUS business in the near term will also not be impacted, expecting continued orders from China.